Reactivation of tuberculosis with mycobacterium bovis infection of the oral mucosa during immunosuppression;Tuberkulosereaktivierung mit mycobacterium-bovis-infektion der mundschleimhaut unter immunsuppression

Deutsche Medizinische Wochenschrift

Volumn 135, Issue 23, 2010, Pages 1179-1181

  Ernst, D ^a   Bange, F C ^a   Rana, A ^a   Baerlecken, N ^a   Puls, F ^a   Schmidt, R E ^a   Stoll, M ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Mycobacterium bovis; Rheumatoid arthritis; TNF inhibitors; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; MOXIFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

AGED; ARTICLE; BACTERIUM CULTURE; BOVINE TUBERCULOSIS; CASE REPORT; CHEILITIS; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GERMANY; HUMAN; MOUTH MUCOSA; MOUTH ULCER; MUCOSA INFLAMMATION; RHEUMATOID ARTHRITIS;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; ARTHRITIS, RHEUMATOID; DIAGNOSIS, DIFFERENTIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; METHOTREXATE; MOUTH MUCOSA; MYCOBACTERIUM BOVIS; OPPORTUNISTIC INFECTIONS; RECURRENCE; TUBERCULOSIS, ORAL;

EID: 77953152736     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0030-1255127     Document Type: Article

References (11)

1. Askling J, Fored C M., Brandt L et al. Time-dependent increase in risk of hospitalisation with infection among swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007 66 1339-1344
2. Burmester G R., Mease P J., Dijkmans B A. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009 68 1863-1869
3. Conraths F J., Geue L, Groschup M H. et al. Zoonosen der Nutz- und Wildtiere und ihre Bedeutung in Deutschland. Bundesgesundheitsblatt 2004 47 633-646
4. Diehl R, Hauer B, Loddenkemper R, Manger B, Krüger K. Empfehlungen für das Tuberkulose-Screening vor Gabe von TNF -α- Inhibitoren bei rheumatischen Erkrankungen. Z Rheumatol 2009 68, 5 411-416
5. Dorman S E., Johnson J L., Goldberg S, Villarino M, Vernon A, Chaisson R E. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Crit Care Med 2009 180 273-280
6. Haroon N, Inman R D. Infectious complications of biological therapy. Current Opin Rheumatol 2009 21 397-403
7. Saag K G., Teng G G., Patkar N M., Anuntiyo J, Finney C, Curtis J R., Paulus H E., Mudano A, Pisu M, Elkins-Melton M, Outman R, Allison J J., Suarez A lmazor M, Bridges S L. Jr, Chatham W W., Hochberg M, MacLean C, Mikuls T, Moreland L W., ODell J, Turkiewicz A M., Furst D E. American College of Rheumatology: American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008 59 762-84
8. Saliu O Y., Sofer C, Stein D S., Schwander S K., Wallis R S. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis 2006 194 486-492
9. Salvana E MT, Salata R A. Infectious complications associated with monoclonal antibodies and related small molecules. Clin Microbiol Rev 2009 22 274-290
10. Wallis R S. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 2008 58 947-952
11. Winthrop K L. Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor-alpha. Ann Rheum Dis 2005 64 Suppl 4 29-30